Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$24.2 million.

  • Taysha Gene Therapies' Free Cash Flow fell 1251.74% to -$24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.2 million, marking a year-over-year decrease of 722.05%. This contributed to the annual value of -$81.6 million for FY2024, which is 612.85% down from last year.
  • Taysha Gene Therapies' Free Cash Flow amounted to -$24.2 million in Q3 2025, which was down 1251.74% from -$20.6 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Free Cash Flow peaked at $12.4 million during Q4 2022, and registered a low of -$49.4 million during Q1 2022.
  • Over the past 4 years, Taysha Gene Therapies' median Free Cash Flow value was -$21.5 million (recorded in 2024), while the average stood at -$22.3 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Free Cash Flow in the last 5 years was 5458.32% (2023), contrasted with its biggest fall of 23008.14% (2023).
  • Over the past 4 years, Taysha Gene Therapies' Free Cash Flow (Quarter) stood at $12.4 million in 2022, then tumbled by 230.08% to -$16.1 million in 2023, then dropped by 13.46% to -$18.3 million in 2024, then tumbled by 32.43% to -$24.2 million in 2025.
  • Its Free Cash Flow was -$24.2 million in Q3 2025, compared to -$20.6 million in Q2 2025 and -$22.0 million in Q1 2025.